NSK-SD and More Benefits

Anti-Inflammatory Effect

We have a human study that shows a single dose of NSK-SD is effective in decreasing inflammation in subjects with high CRP levels.

  • Jeske et al. 2011 (unpublished) - 10 subjects that each had three or more cardiovascular risk factors present were given a single dose of 2,000FU of NSK-SD and the CRP levels in the blood were measured over 24 hours following intake. Mean CRP levels decreased progressively for 12 hours post-dose. The greatest effect was observed in patients with higher CRP levels pre-treatment. The highest CRP value dropped by 72%.

Why do we care about CRP levels?

Elevation in CRP levels have been associated with the following:

  • Cardiovascular Disease

  • Atherosclerosis

  • Heart Disease Risk

  • Systemic Inflammation

  • Metabolic Syndrome

  • Trauma, Cancer, Infection, etc.

In 2003 AHA and CDC published a joint scientific statement recommending the measurement of CRP for clinical and public health assessment of coronary heart disease and stroke.

Cognitive Health Benefits

(Zhang et al 2026) - Subjects: 120 adults with asymptomatic intracranial and/or carotid artery stenosis

•In a randomized controlled trial with 6 months of nattokinase supplementation (8,000 FU/day), subjects experienced enhanced visuospatial cognitive function

NSK-SD and AGEs

(Yamaguchi et al 2024) - NSK-SD has shown to alleviate glycogen deposition in renal tubules and elevated CRP in STZ-induced diabetic mice via the inhibition of AGEs formation.

•The extended interaction of proteins, amino acids or lipids with sugars leads to Advanced Glycation End Products (AGE) formation, which causes aging and is also involved in the progression of diabetes and various complications.

•Patent approved in JP: Advanced Glycation Endproduct Inhibitor (Patent No. 7804957)

Contact Us to Receive the Full Studies